B.Riley FBR analyst Andrew D’silva maintained a Buy rating on Kindred Biosciences (KIN) on May 10 and set a price target of $18. The company’s shares closed on Friday at $9.27, close to its 52-week low of $8.04.
D’silva said:
“We believe additional progress with any of these studies could be a needle mover for shares. KIN typically selects targets that have ~$10M–$100M market opportunities but its pipeline does have candidates with TAMs several times higher, and has numerous biologic and small molecule candidates that target everything from cancer in dogs and anemia in cats to equine gastric ulcers.”
According to TipRanks.com, D’silva is a 4-star analyst with an average return of 6.6% and a 39.6% success rate. D’silva covers the Healthcare sector, focusing on stocks such as EyePoint Pharmaceuticals Inc, Sensus Healthcare Inc, and Anixa Biosciences Inc.
Currently, the analyst consensus on Kindred Biosciences is a Strong Buy with an average price target of $19.50, representing an 110.4% upside. In a report issued on April 26, Cantor Fitzgerald also maintained a Buy rating on the stock with a $25 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $15.75 and a one-year low of $8.04. Currently, Kindred Biosciences has an average volume of 226.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Kindred Biosciences, Inc. is a development-stage biopharmaceutical company, which focuses on saving and improving the lives of pets. The company was founded by Richard Chin and Denise M. Bevers on September 25, 2012 and is headquartered in Burlingame, CA.
